Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HPZ
|
|||
| Former ID |
DAP001448
|
|||
| Drug Name |
Tocilizumab
|
|||
| Synonyms |
Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Approved | [1], [2] | |
| Juvenile idiopathic arthritis [ICD-11: FA24; ICD-9: 714.3] | Phase 3 | [1], [2] | ||
| Company |
Roche; Genentech
|
|||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D02234 | |||
| SuperDrug ATC ID |
L04AC07
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 6 receptor (IL6R) | Target Info | Modulator | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Reactome | MAPK3 (ERK1) activation | |||
| MAPK1 (ERK2) activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Senescence and Autophagy in Cancer | ||||
| IL-6 signaling pathway | ||||
| Differentiation Pathway | ||||
| Interleukin-6 signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881). | |||
| REF 2 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | |||
| REF 3 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.